Association of heart rate with mortality in sinus rhythm and atrial fibrillation in heart failure with preserved ejection fraction.


Journal

European journal of heart failure
ISSN: 1879-0844
Titre abrégé: Eur J Heart Fail
Pays: England
ID NLM: 100887595

Informations de publication

Date de publication:
04 2019
Historique:
received: 01 06 2018
revised: 13 11 2018
accepted: 19 11 2018
pubmed: 31 1 2019
medline: 25 8 2020
entrez: 31 1 2019
Statut: ppublish

Résumé

To assess the association between atrial fibrillation (AF) and mortality, and also the association between resting heart rate (HR) and mortality in both sinus rhythm (SR) and AF in patients with heart failure with preserved ejection fraction (HFpEF). A total of 9090 patients with HFpEF (ejection fraction ≥ 50%) were included from the Swedish Heart Failure registry; 4296 (47%) had SR and 4794 (53%) had AF. Patients with AF were older (80.3 vs. 75.0 years) and more symptomatic compared with patients in SR. The outcome measure was all-cause mortality. The adjusted hazard ratio (95% confidence interval) for AF vs. SR was 1.21 (1.11-1.32). Compared with HR ≤ 60 b.p.m., the adjusted hazard ratios (95% confidence interval) were in SR: 1.06 (0.92-1.21) for HR 61-70 b.p.m., 1.30 (1.12-1.52) for HR 71-80 b.p.m., 1.27 (1.07-1.51) for HR 81-90 b.p.m., and 1.77 (1.45-2.17) for HR > 90 b.p.m. Due to non-proportional hazards in AF, hazard ratios were estimated in three time periods. Compared with HR ≤ 60 b.p.m., the adjusted hazard ratios (95% confidence interval) were in AF: 1.30 (1.07-1.57), 1.07 (0.83-1.39), and 1.01 (0.70-1.48) for HR 61-70 b.p.m., 1.35 (1.12-1.62), 0.99 (0.77-1.27), and 0.96 (0.66-1.40) for HR 71-80 b.p.m., 1.41 (1.16-1.73), 1.01 (0.76-1.36), and 0.79 (0.51-1.22) for HR 81-90 b.p.m., and 1.78 (1.46-2.17), 1.08 (0.80-1.46), and 0.73 (0.46-1.17) for HR > 90 b.p.m., during 0-2, 2-4, and 4-6 years of follow-up, respectively. In a large and unselected cohort of patients with HFpEF, AF was independently associated with all-cause mortality. A higher HR was associated with increased mortality in SR. In AF, the effect of a higher HR on mortality was only present during the first years of follow-up, with convergence in outcomes according to baseline HR groups over long-term follow-up.

Identifiants

pubmed: 30698317
doi: 10.1002/ejhf.1389
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

471-479

Subventions

Organisme : Regional ALF agreement between Västra Götalandsregionen and University of Gothenburg
ID : ALFGBG-721961
Pays : International
Organisme : Regional ALF agreement between Stockholm County Council and Karolinska Institutet
ID : 20160329
Pays : International
Organisme : Magnus Bergvall Foundation
ID : 2017-02054
Pays : International
Organisme : Åke Wiberg Foundation
ID : M17-0089
Pays : International
Organisme : Swedish Heart and Lung Association
ID : E101/16
Pays : International
Organisme : Karolinska Institutet Foundations and Funds
ID : 2016fobi47721
Pays : International
Organisme : Mats Kleberg Foundation
ID : 2017-00096
Pays : International
Organisme : Swedish Heart-Lung Foundation
ID : 20170453
Pays : International
Organisme : Swedish Heart-Lung Foundation
ID : 20160522
Pays : International
Organisme : Swedish Heart-Lung Foundation
ID : 20160525
Pays : International
Organisme : Swedish Society of Cardiology
Pays : International
Organisme : Swedish Association of Local Authorities and Regions
Pays : International
Organisme : Swedish National Board of Health and Welfare
Pays : International

Commentaires et corrections

Type : CommentIn

Informations de copyright

© 2019 The Authors. European Journal of Heart Failure © 2019 European Society of Cardiology.

Auteurs

Ulrik Sartipy (U)

Heart and Vascular Theme, Karolinska University Hospital, Stockholm, Sweden.
Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.

Gianluigi Savarese (G)

Department of Medicine, Karolinska Institutet, Stockholm, Sweden.

Ulf Dahlström (U)

Department of Cardiology and Department of Medical and Health Sciences, Linköping University, Linköping, Sweden.

Michael Fu (M)

Department of Medicine, Sahlgrenska University Hospital/Östra Hospital, Gothenburg, Sweden.

Lars H Lund (LH)

Heart and Vascular Theme, Karolinska University Hospital, Stockholm, Sweden.
Department of Medicine, Karolinska Institutet, Stockholm, Sweden.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH